Blood Cancer Talks

In this episode of Blood Cancer Talks, we have Dr. Adrian Minson from the Peter MacCallum Cancer Centre to discuss the latest developments in lymphoma presented at the recent EHA and ICML meetings in June 2025. The episode focuses primarily on the emerging role of bispecific antibodies in various combinations and treatment settings for diffuse large B-cell lymphoma (DLBCL).

Key Clinical Trials Discussed
1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL
2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL
3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)
4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL
5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL
6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL
7. Additional Studies Mentioned:
R-Pola-Glo Frail Study
DLBCL Classification

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk